The Australian market has recently shown positive momentum, with the ASX200 closing up 0.6% at 8,535 points, driven by strong performances in the Industrials and Financials sectors. As investors navigate these shifting landscapes, identifying undervalued stocks like Domino's Pizza Enterprises and others could offer potential opportunities for those seeking value in a buoyant yet selective market environment.
Name | Current Price | Fair Value (Est) | Discount (Est) |
IDP Education (ASX:IEL) | A$12.38 | A$24.32 | 49.1% |
COSOL (ASX:COS) | A$1.00 | A$1.92 | 47.8% |
Atlas Arteria (ASX:ALX) | A$5.00 | A$9.11 | 45.1% |
Symal Group (ASX:SYL) | A$1.98 | A$3.62 | 45.2% |
Mesoblast (ASX:MSB) | A$2.97 | A$5.70 | 47.9% |
ReadyTech Holdings (ASX:RDY) | A$3.17 | A$5.73 | 44.7% |
29Metals (ASX:29M) | A$0.195 | A$0.39 | 49.9% |
Integral Diagnostics (ASX:IDX) | A$2.92 | A$5.74 | 49.1% |
Pantoro (ASX:PNR) | A$0.135 | A$0.25 | 47% |
Sandfire Resources (ASX:SFR) | A$10.54 | A$19.34 | 45.5% |
Click here to see the full list of 54 stocks from our Undervalued ASX Stocks Based On Cash Flows screener.
Let's dive into some prime choices out of the screener.
Overview: Domino's Pizza Enterprises Limited operates retail food outlets and has a market cap of A$3.21 billion.
Operations: The company's revenue from its restaurants segment is A$2.38 billion.
Estimated Discount To Fair Value: 37.3%
Domino's Pizza Enterprises is trading at A$33.35, significantly below its estimated fair value of A$53.18, indicating potential undervaluation based on cash flows. Although revenue growth is modest at 3.8% annually, earnings are expected to grow significantly by 24.1% per year over the next three years, outpacing the broader Australian market's growth rate of 12.3%. However, a high debt level and an unsustainable dividend coverage may pose challenges despite strong profit forecasts and a high future return on equity of 26.2%.
Overview: Mesoblast Limited is involved in the development of regenerative medicine products across Australia, the United States, Singapore, and Switzerland, with a market cap of A$3.78 billion.
Operations: The company generates revenue from the development of its cell technology platform for commercialization, amounting to $5.90 million.
Estimated Discount To Fair Value: 47.9%
Mesoblast, trading at A$2.97, is significantly undervalued compared to its fair value estimate of A$5.7. Despite recent shareholder dilution and volatile share prices, the company shows promising prospects with expected annual revenue growth of 49% and anticipated profitability within three years. Recent developments include the U.S. commercial launch of Ryoncil® for pediatric SR-aGvHD, targeting a market exceeding $1 billion annually, supported by a robust balance sheet and strategic cash management amid ongoing equity offerings totaling AUD 260 million.
Overview: Nick Scali Limited, with a market cap of A$1.46 billion, is involved in the sourcing and retailing of household furniture and related accessories across Australia, the United Kingdom, and New Zealand.
Operations: The company's revenue is primarily derived from the retailing of furniture, amounting to A$492.63 million.
Estimated Discount To Fair Value: 44.3%
Nick Scali, trading at A$16.86, is undervalued based on its discounted cash flow valuation, with a fair value estimate of A$30.28. Despite a decrease in interim dividend to 30 cents per share from 35 cents last year and lower net income of A$30.04 million compared to A$43.01 million previously, it remains attractive due to forecasted earnings growth of 12.61% annually and strong return on equity projections reaching 28.5% in three years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:DMP ASX:MSB and ASX:NCK.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。